CeriBell (CBLL) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CeriBell (CBLL) has outperformed Stereotaxis (STXS) over the past year, gaining 79.5% versus a loss of 59.4%. CeriBell is the larger company by market cap ($1.06 billion vs $95.0 million), about 11.2 times the size. CeriBell converts more of its revenue into profit, with a net margin of -60.0% versus -66.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBLL | STXS |
|---|---|---|
| Share price | $27.39 | $0.9422 |
| Market cap | $1.06B | $95.03M |
| 1-day change | +6.37% | -6.71% |
| YTD return | +24.90% | -59.03% |
| 1-year return | +79.49% | -59.39% |
| 5-year return | — | -84.16% |
| EPS (TTM) | $-1.95 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $89.06M | $32.38M |
| Revenue growth (YoY) | +36.09% | +20.28% |
| Net income (latest FY) | $-53.41M | $-21.64M |
| Gross margin | 87.89% | 52.73% |
| Operating margin | -65.57% | -68.30% |
| Net margin | -59.97% | -66.85% |
| 52-week high | $28.89 | $2.86 |
| 52-week low | $14.87 | $0.80 |
| Distance from 52-week high | -5.19% | -67.06% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +15.26% | +218.40% |
| Average volume | 452.64K | 715.12K |
| Shares outstanding | 38.84M | 100.86M |
| Employees | 327 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CeriBell is about 11.2 times larger than Stereotaxis by market value ($1.06B vs $95.03M).
- CBLL has outperformed STXS by 138.9 percentage points over the past year.
- CeriBell is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -66.8 cents for Stereotaxis.
- CeriBell grew revenue faster in its latest fiscal year (+36.09% vs +20.28%).
About CeriBell
CBLL stock →CeriBell, Inc. operates as a medical technology company in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
CBLL vs STXS FAQ
Which is bigger, CeriBell or Stereotaxis?
CeriBell (CBLL) is larger, with a market capitalization of $1.06B compared with $95.03M for Stereotaxis (STXS).
Which stock has performed better over the past year, CBLL or STXS?
CBLL returned +79.49% over the past 12 months, compared with -59.39% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are CeriBell and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.